Literature DB >> 15143083

Failure pattern and factors predictive of local failure in rhabdomyosarcoma: a report of group III patients on the third Intergroup Rhabdomyosarcoma Study.

Moody D Wharam1, Jane Meza, James Anderson, John C Breneman, Sarah S Donaldson, Thomas J Fitzgerald, Jeff Michalski, Lisa A Teot, Eugene S Wiener, William H Meyer.   

Abstract

PURPOSE: To analyze patterns of failure and factors predictive of local treatment failure in children enrolled on the third Intergroup Rhabdomyosarcoma Study who had either biopsy only or subtotal resection of their primary tumor, had no distant metastases, and received radiation therapy for local control. PATIENTS AND METHODS: Treatment failure was categorized as local, regional nodal, or distant metastatic. The 5-year cumulative risk of failure was estimated for each category and factors predictive of local failure risk were determined using the Cox model and binary recursive partitioning.
RESULTS: The estimated 5-year cumulative incidence rates by failure category were: total local (with or without concurrent regional or distant failure), 19%; total regional nodal, 2%; total distant, 11%; and death from toxicity or unknown recurrence type, 4%. Lymph node involvement at diagnosis was the single factor most predictive of increased total local failure risk (5-year cumulative incidence 32%) compared with children with negative nodes or unknown node status (16%). No significant effect on local failure risk was observed by total radiotherapy dose over the prescribed range of 41.4 Gy to 50.4 Gy. For all patients (N = 405), the estimated 5-year failure-free survival and overall survival were, respectively, 70% and 78%.
CONCLUSION: Local failure after radiotherapy for group III rhabdomyosarcoma patients is the predominant type of relapse. Involved lymph nodes at diagnosis predict a higher risk of local and distant treatment failure compared with patients whose lymph nodes are negative.

Entities:  

Mesh:

Year:  2004        PMID: 15143083     DOI: 10.1200/JCO.2004.08.124

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  21 in total

Review 1.  Rhabdomyosarcoma: current challenges and their implications for developing therapies.

Authors:  Simone Hettmer; Zhizhong Li; Andrew N Billin; Frederic G Barr; D D W Cornelison; Alan R Ehrlich; Denis C Guttridge; Andrea Hayes-Jordan; Lee J Helman; Peter J Houghton; Javed Khan; David M Langenau; Corinne M Linardic; Ranadip Pal; Terence A Partridge; Grace K Pavlath; Rossella Rota; Beat W Schäfer; Janet Shipley; Bruce Stillman; Leonard H Wexler; Amy J Wagers; Charles Keller
Journal:  Cold Spring Harb Perspect Med       Date:  2014-11-03       Impact factor: 6.915

2.  Local therapy for rhabdomyosarcoma of the hands and feet: is amputation necessary? A report from the Children's Oncology Group.

Authors:  Trang H La; Suzanne L Wolden; Zheng Su; Corinne Linardic; R Lor Randall; Douglas S Hawkins; Sarah S Donaldson
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-06-18       Impact factor: 7.038

3.  Processes for quality improvements in radiation oncology clinical trials.

Authors:  T J FitzGerald; Marcia Urie; Kenneth Ulin; Fran Laurie; Jeffrey Yorty; Richard Hanusik; Sandy Kessel; Maryann Bishop Jodoin; Gani Osagie; M Giulia Cicchetti; Richard Pieters; Kathleen McCarten; Nancy Rosen
Journal:  Int J Radiat Oncol Biol Phys       Date:  2008       Impact factor: 7.038

4.  Radiation for bone metastases in Ewing sarcoma and rhabdomyosarcoma.

Authors:  Dana L Casey; Leonard H Wexler; Paul A Meyers; Heather Magnan; Alexander J Chou; Suzanne L Wolden
Journal:  Pediatr Blood Cancer       Date:  2014-10-24       Impact factor: 3.167

5.  Evolution of Care of Orbital Tumors with Radiation Therapy.

Authors:  Myrsini Ioakeim-Ioannidou; Shannon M MacDonald
Journal:  J Neurol Surg B Skull Base       Date:  2020-08-24

6.  Clinical features and outcomes in patients with Ewing sarcoma and regional lymph node involvement.

Authors:  Mark A Applebaum; Robert Goldsby; John Neuhaus; Steven G DuBois
Journal:  Pediatr Blood Cancer       Date:  2011-12-19       Impact factor: 3.167

7.  Local control with reduced-dose radiotherapy for low-risk rhabdomyosarcoma: a report from the Children's Oncology Group D9602 study.

Authors:  John Breneman; Jane Meza; Sarah S Donaldson; R Beverly Raney; Suzanne Wolden; Jeff Michalski; Fran Laurie; David A Rodeberg; William Meyer; David Walterhouse; Douglas S Hawkins
Journal:  Int J Radiat Oncol Biol Phys       Date:  2011-11-19       Impact factor: 7.038

8.  Regional nodal involvement and patterns of spread along in-transit pathways in children with rhabdomyosarcoma of the extremity: a report from the Children's Oncology Group.

Authors:  Trang H La; Suzanne L Wolden; David A Rodeberg; Douglas S Hawkins; Kenneth L Brown; James R Anderson; Sarah S Donaldson
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-06-11       Impact factor: 7.038

9.  Management of pediatric head and neck rhabdomyosarcoma: A case-series of 36 patients.

Authors:  Joanna Radzikowska; Wojciech Kukwa; Andrzej Kukwa; Anna M Czarnecka; Maciej Kawecki; Fei Lian; Cezary Szczylik; Antoni Krzeski
Journal:  Oncol Lett       Date:  2016-09-01       Impact factor: 2.967

10.  Outcome of patients with localized orbital sarcoma who relapsed following treatment on Intergroup Rhabdomyosarcoma Study Group (IRSG) Protocols-III and -IV, 1984-1997: a report from the Children's Oncology Group.

Authors:  Beverly Raney; Winston Huh; Douglas Hawkins; Andrea Hayes-Jordan; Lynn Million; David Rodeberg; Lisa Teot; James Anderson
Journal:  Pediatr Blood Cancer       Date:  2012-09-07       Impact factor: 3.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.